FINWIRES · TerminalLIVE
FINWIRES

行业动态:医疗保健股周四下午上涨

By

-- 周四下午,医疗保健类股上涨,纽约证券交易所医疗保健指数上涨2.5%,道富医疗保健精选行业SPDR ETF (XLV)上涨2.3%。 iShares生物技术ETF (IBB)上涨2%。 公司新闻方面,礼来公司(LLY)上调了全年业绩预期,并公布了超出市场预期的第一季度业绩,其产品Mounjaro的销售额增长超过一倍。礼来股价应声上涨10%。 美国食品药品监督管理局(FDA)提议将替拉肽、索玛鲁肽和利拉鲁肽从503B药品清单中移除,理由是目前临床上没有必要将这三种药物的原料药外包给其他机构进行配制。礼来公司生产的替拉肽以Mounjaro的商品名销售,用于治疗2型糖尿病,并以Zepbound的商品名销售,用于慢性体重管理。诺和诺德 (NVO) 生产司美格鲁肽(商品名 Ozempic,用于治疗 2 型糖尿病,以及 Wegovy,用于慢性体重管理)和利拉鲁肽(商品名 Victoza,用于治疗 2 型糖尿病,以及 Saxenda,用于慢性体重管理)。诺和诺德股价上涨 5.0%。 诺和康 (NVCR) 股价在公司公布第一季度业绩后飙升 28%。

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM